for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca announces results from SYMBICORT study

Aug 31 (Reuters) - AstraZeneca Plc

* SYMBICORT demonstrated comparable risk of serious asthma-related events and lower risk of asthma exacerbations compared to Budesonide alone

* Shared results with FDA and will soon be discussing next steps in line with post-marketing requirements Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up